吉非替尼
医学
卡铂
危险系数
内科学
肺癌
临床终点
腺癌
人口
肿瘤科
置信区间
紫杉醇
化疗
表皮生长因子受体
癌症
随机对照试验
顺铂
环境卫生
作者
Tony Mok,Yi‐Long Wu,Sumitra Thongprasert,James Chih‐Hsin Yang,Da-Tong Chu,Nagahiro Saijo,Patrapim Sunpaweravong,Baohui Han,Benjamin Margono,Yukito Ichinose,Yutaka Nishiwaki,Yuichiro Ohe,Jin-Ji Yang,Busyamas Chewaskulyong,Haiyi Jiang,Emma Duffield,Claire Watkins,Alison Armour,Masahiro Fukuoka
标识
DOI:10.1056/nejmoa0810699
摘要
Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients with non–small-cell lung cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI